Evidence map›Paper›PMID 42726373›Full record

ArticleAdvances in therapy2026

Antihypertensive Medication Patterns in Patients with Hypertension that is Harder to Control: Insights from the EnligHTN Study.

Jesper N Bech, Terry McCormack, Vivek Bhalla, Naomi R Ben Dor, Julian Segura, Søren Hougaard Christiansen, Ina T Andersen, Clement Erhard, Kirsty M Rhodes, Tom Norris and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jesper N BechUniversity Clinic in Nephrology and Hypertension, Gødstrup Hospital and Aarhus University, Herning, Denmark. Jesper.noergaard.bech@goedstrup.rm.dk.
Terry McCormackInstitute of Clinical and Applied Health Research, Hull York Medical School, Hull, UK.
Vivek BhallaStanford Hypertension Center, Stanford University School of Medicine, Stanford, CA, USA.
Naomi R Ben DorTau-AZ Beam, Ramat Aviv, Tel Aviv, Israel.
Julian SeguraHypertension Unit, Department of Nephrology, Hospital Universitario 12 de Octubre, Madrid, Spain.
Søren Hougaard ChristiansenDepartment of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus N, Denmark.
Ina T AndersenDepartment of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus N, Denmark.
Clement ErhardBioPharmaceuticals Medical Evidence Real World Data Science, AstraZeneca, Cambridge, UK.
Kirsty M RhodesBioPharmaceuticals Medical Evidence Statistics, AstraZeneca, Cambridge, UK.
Tom NorrisCardiovascular, Renal and Metabolism Evidence Strategy, BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden.
Esteban CotoCardiovascular, Renal and Metabolism, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, USA.
Joachim WeilMedizinische Klinik II, Sana Kliniken Lübeck GmbH, Lübeck, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMany patients with hypertension have hypertension that is harder to control (defined as needing ≥ 2 antihypertensive medications) and fail to achieve adequate blood pressure (BP) control. We assessed treatment patterns and BP outcomes in a large, multinational cohort of patients initiating a third antihypertensive class whilst remaining on a stable regimen of two antihypertensives from different classes.

methodsEnligHTN is an observational, longitudinal cohort study on hypertension management and outcomes. Data from the USA, UK, Germany, Spain, and Israel from 2018 to 2023, and Denmark from 2018 to 2024, were extracted from de-identified electronic medical records, claims data, and health registry sources. Adult patients with diagnosed hypertension were included if they initiated a third antihypertensive (index date) whilst remaining on a stable two-drug regimen. Baseline demographics and clinical characteristics, treatment patterns from index to 24 months, and BP control at 12 and 24 months from index were described.

resultsData from 64,501 patients were included. Across countries and common third antihypertensive classes, the proportion of patients who discontinued their third medication after index ranged from 54% to 100% at 12 months and from 67% to 100% at 24 months. Among a subcohort of patients with BP measurements at 12 months from index, BP was below target in 23-89%.

conclusionsMany patients with harder-to-control hypertension discontinued their third class of antihypertensive within 1 year, and numerous did not achieve adequate BP control. These findings highlight a significant gap in current hypertension management and underscore the need for adherence-focused treatment strategies to improve treatment persistence and BP outcomes in these patients.

Indexed as

AntihypertensivesBlood pressure controlHarder-to-control hypertensionHypertensionMedication adherenceObservational cohort studyReal-world evidenceTreatment persistence

Identifiers

PMID42726373

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.